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Vitamin D deficiency is associated with higher all-cause mortality, but associations with specific 
causes of death are unclear. We investigated the association between circulating 25-hydroxyvitamin 
D (25(OH)D) concentration and cause-specific mortality using a case-cohort study within the 
Melbourne Collaborative Cohort Study (MCCS). Eligibility for the case-cohort study was restricted to 
participants with baseline dried blood spot samples and no pre-baseline diagnosis of cancer. These 
analyses included participants who died (n = 2307) during a mean follow-up of 14 years and a sex-
stratified random sample of eligible cohort participants (‘subcohort’, n = 2923). Concentration of 
25(OH)D was measured using liquid chromatography-tandem mass spectrometry. Cox regression, 
with Barlow weights and robust standard errors to account for the case-cohort design, was used to 
estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for cause-specific mortality in 
relation to 25(OH)D concentration with adjustment for confounders. 
 
Circulating 25(OH)D concentration was inversely associated with risk of death due to cancer (HR per 
25 nmol/L increment = 0.88, 95% CI 0.78–0.99), particularly colorectal cancer (HR = 0.75, 95% CI 
0.57–0.99). Higher 25(OH)D concentrations were also associated with a lower risk of death due to 
diseases of the respiratory system (HR = 0.62, 95% CI 0.43–0.88), particularly chronic obstructive 
pulmonary disease (HR = 0.53, 95% CI 0.30–0.94), and diseases of the digestive system (HR = 0.44, 
95% CI 0.26–0.76). Estimates for diabetes mortality (HR = 0.64, 95% CI 0.33–1.26) and cardiovascular 
disease mortality (HR = 0.90, 95% CI 0.76–1.07) lacked precision.  
 
The findings suggest that vitamin D might be important for preventing death due to some cancers, 
respiratory diseases, and digestive diseases. 
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Many cohort studies have found that plasma 25-hydroxyvitamin D [25(OH)D] concentration, which is 
currently considered to provide the best measure of vitamin D status, is inversely associated with all-
cause mortality [1-5]. A Mendelian randomisation study reaffirmed this association by 
demonstrating an inverse association between genetically-determined 25(OH)D and all-cause 
mortality of similar magnitude to that found for plasma 25(OH)D [6]. Complementing these findings, 
meta-analyses of randomised controlled trials (RCTs) have shown that vitamin D3 supplementation is 
associated with lower all-cause mortality, although the magnitude of benefit appears to be small [2, 
7]. With mounting evidence that vitamin D might be important for reducing mortality, it is important 
to investigate which specific causes of death are associated with vitamin D status. 
 
The most commonly investigated causes of death in relation to 25(OH)D have been cancer and 
cardiovascular disease, with most studies reporting inverse associations, but data on specific cancers 
and cardiovascular diseases are lacking [1]. Associations with other causes of death, particularly less 
common causes, are unclear due to limited data [1]. 
 
In light of the lack of data for many causes of death, we sought to investigate the association 
between circulating concentration of 25(OH)D and various cause-specific mortality outcomes using a 
case-cohort study nested within a population-based prospective cohort study. To explore the 
potential influence of reverse causation, we performed sensitivity analyses excluding the first two 
years of follow-up and, for the main causes of death, evaluated associations for participants who 




The Melbourne Collaborative Cohort Study (MCCS) is a prospective cohort study of 41,513 residents 
(24,469 women and 17,044 men) in Melbourne, Victoria, Australia, who were aged 27–76 (99% aged 
40–69) years when recruited between 1990 and 1994. Details of the study have been published [8]. 
Briefly, at recruitment participants attended study centres where they completed a 121-item food 
frequency questionnaire, were interviewed about lifestyle and medical history, and had 
anthropometric measurements and blood samples collected. For participants recruited from the 
second year of recruitment onwards (i.e. for approximately 75% of participants), a whole blood 
sample was spotted onto Guthrie cards; these dried blood spot samples were stored at room 
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temperature in dark conditions. Approximately four years after recruitment, participants were 
mailed a self-administered questionnaire (wave 2), which included a question on general health 
status, rated as excellent, very good, good, fair, or poor. Participants are regularly sent study 
newsletters and asked to update contact details. This information, plus alternative contacts and 
searching the electoral roll was used to identify participants who had left Australia. 
 
A case-cohort study was set up to investigate circulating concentration of 25(OH)D and risk of 
incident breast, prostate, and colorectal cancers, diabetes, and mortality. By the time it began, the 
baseline plasma samples for many of the participants diagnosed with cancer and those who had died 
from cardiovascular disease had been used. We, therefore, used archived dried blood spots for 
measurement of 25(OH)D. Eligibility for the case-cohort study was restricted to participants who had 
dried blood spot samples available from baseline and no pre-baseline diagnosis of cancer (n = 
29,205). Results pertaining to incident breast, prostate, and colorectal cancers [9], diabetes [10], and 
all-cause mortality [11] have been published. As per the investigation of all-cause mortality, the 
cause-specific mortality analyses herein included all eligible participants who died by 31 December 
2007 (n = 2410) and the subcohort, a sex-stratified random sample of 2996 participants. Participants 
for whom 25(OH)D measurements were not performed, with missing data for key confounding 
variables included in all models, or with extreme values for total daily energy intake (<1st and >99th 
sex-specific percentiles) were excluded. In analyses of causes of death adjusted for additional 
confounders, participants with missing data for the relevant covariates were excluded. 
 
The Cancer Council Victoria’s Human Research Ethics Committee approved the study protocol and 
participants provided written consent to participate and for the investigators to obtain access to 
their medical records.  
 
2.2 Measurement of 25-hydroxyvitamin D 
Concentrations of 25(OH)D2 and 25(OH)D3 in baseline dried blood spot samples were measured by 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) in the laboratory of D.W.E and 
summed to yield total 25(OH)D as previously described [12-14]. Samples were processed in random 
order and laboratory analysts were blind to outcome status of participants. The laboratory uses 
National Institute of Standards and Technology (NIST) Standard Reference Materials and participates 
in the Vitamin D External Quality Assessment Scheme (DEQAS). The relative assay inaccuracies using 
four NIST sera calibrants were +2.3, +3.4, +2.0 and –0.5% at concentrations of 17.7, 32.2, 49.6, and 
61.85 nmol/L, respectively, with an overall inaccuracy of 2.0% (international standards for dried 
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blood spots do not yet exist). A repeatability study of 493 duplicates demonstrated that the dried 
blood spot 25(OH)D measurements have high reliability [13]. Methods for removing batch effects 
and seasonal variation, and conversion of 25(OH)D measured in dried blood spots to plasma-
equivalent concentrations have been described [10, 11, 13]. All results presented are for batch- and 
season-adjusted plasma-equivalent 25(OH)D concentrations. 
 
2.3 Ascertainment of deaths 
Vital status and cause of death were identified through record linkage to death certificates issued in 
Victoria by the Registry of Births, Deaths and Marriages, and linkage to the National Death Index 
compiled by the Australian Institute of Health and Welfare. For cancer mortality, cause of death was 
ascertained by linkage to the Victorian Cancer Registry (VCR), which in some cases provided a more 
accurate indication of the primary site of the cancer. Causes of death were coded according to the 
WHO International Classification of Diseases, 9th revision (ICD-9) and 10th revision (ICD-10) and 
grouped based on ICD-10 chapters (Supplementary Table 1). For the purposes of analysis, only 
malignant neoplasms (ICD-9 140–209.3 or ICD-10 C00–C97) were included in the classification of 
cancer. Colorectal cancer included malignant neoplasm of the colon, rectosigmoid junction, or 
rectum (ICD-9 153–154.1 or ICD-10 C18–C20). Analyses of breast cancer mortality were restricted to 
women (ICD-9 174 malignant neoplasm of female breast or ICD-10 C50). Cardiovascular disease 
included all diseases of the circulatory system (ICD-9 390–459 or ICD-10 I00–I99). 
 
2.4 Statistical analysis 
All statistical analyses were conducted using Stata 13.1 (Stata Corporation, College Station, TX, USA). 
Analyses were performed for all causes of death or disease groups for which there were at least 50 
deaths (except for external causes, for which analyses were not performed). Cox regression was 
used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for each cause of death per 
25 nmol/L increment in 25(OH)D by modelling 25(OH)D continuously, and according to sex-specific 
quartiles of 25(OH)D (relative to the lowest quartile) based on the distribution of batch- and season-
adjusted plasma-equivalent concentrations of 25(OH)D in the subcohort. We also performed 
analyses for 25(OH)D3 separately, but results were similar since few participants had detectable 
circulating 25(OH)D2 (n = 62) and only results for total 25(OH)D are presented. Barlow’s method and 
robust standard errors were used to account for the case-cohort design [15]. Age was the timescale 
and all models were stratified by country of birth (Australia/New Zealand/northern Europe versus 
southern Europe) and sex (except for breast cancer mortality and prostate cancer mortality). Follow-
up began at baseline attendance and ended at the earliest of: date of death, date a participant left 
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Australia, or 31 December 2007. In the analyses for each cause of death, subcohort participants who 
died due to other causes were censored on the day of death, while non-subcohort participants who 
died due to other causes were excluded.  
 
For each cause of death, potential confounders were selected using a causal diagram based on 
existing literature. The set of confounders included in analyses differed for each cause of death 
(Supplementary Table 2), but all models were adjusted for: educational attainment (primary school 
or less, some secondary/technical school, completed secondary school, tertiary qualification), 
socioeconomic status (quintiles of an area-based measure of relative socioeconomic disadvantage, 
based on residential postcodes at baseline), smoking status (never, former, current smoker), alcohol 
intake (lifetime abstainer, former drinker, current low intake, current medium intake, current high 
intake; current drinkers were grouped into sex-specific tertiles of alcohol consumed per day based 
on the subcohort), physical activity (four categories reflecting the intensity and frequency of 
recreational activity over the last 6 months: none, low, moderate, high), waist circumference (sex-
specific quartiles based on the distribution of measurements in the subcohort), Mediterranean diet 
score (grouped into 3 categories: low, moderate, high adherence to a Mediterranean dietary 
pattern), and total daily energy intake (sex-specific quartiles based on the subcohort). Analyses of 
death due to strongly smoking-related causes—i.e. lung cancer, cardiovascular disease (including all 
subgroupings), and respiratory diseases (including subgroupings)—were adjusted for smoking status 
and amount smoked (never, former light smoker [˂20 cigarettes/day], former heavy smoker [≥20 
cigarettes/day], current light smoker [˂20 cigarettes/day], current heavy smoker [≥20 
cigarettes/day]; former and current smokers were divided into light/heavy smokers based on the 
median number of cigarettes smoked per day). For these causes of death, in exploratory analyses we 
also evaluated adjustment for smoking duration or pack-years of smoking (instead of amount 
smoked), but results were similar so only the results for smoking adjusted by smoking status and 
amount are presented. Models for breast cancer mortality included additional adjustment for parity 
(no children, any children). Menopausal status was not included in the models because after 
accounting for age at baseline there was no association between menopausal status and 25(OH)D. 
Use of oral contraceptives and hormone replacement therapy were not associated with 25(OH)D 
and were therefore not included as confounders. Data on family history of breast cancer was not 
available. Analyses of death due to endocrine, nutritional and metabolic diseases and cardiovascular 
disease were additionally adjusted for history of hypertension, heart attack, stroke, angina, and 
diabetes. Models for respiratory disease mortality were additionally adjusted for history of 
hypertension, heart attack, stroke, angina, and asthma. There was no evidence of violation of the 
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proportional hazards assumption, which was assessed by fitting interactions between each covariate 
separately (modelled as a time varying effect) and attained age. 
 
2.5 Subgroup analyses 
Because we had previously found that 25(OH)D was inversely associated with incident colorectal 
cancer for women but not men in the MCCS [9], for colorectal cancer mortality we tested an 
interaction between 25(OH)D (modelled continuously) and sex.  
 
To investigate possible effect modification by baseline disease status, for cardiovascular disease 
mortality we assessed an interaction between continuous 25(OH)D and history of cardiovascular 
disease (heart attack, stroke, or angina). 
 
2.6 Sensitivity analyses 
To mitigate possible reverse causation, sensitivity analyses were undertaken in which follow-up 
began two years after baseline. 
 
For cancer mortality and cardiovascular mortality (the most common causes of death), we 
performed analyses restricted to participants who completed the wave 2 questionnaire 
approximately four years after baseline and reported being in good, very good, or excellent health. 
For these analyses, follow-up began on the date of completion of the wave 2 questionnaire. These 
sensitivity analyses were not possible for the other causes of death presented here because there 
were too few deaths in this restricted subsample of healthy participants (44 due to endocrine, 
nutritional and metabolic diseases, 51 due to diseases of the nervous system, 38 due to diseases of 
the respiratory system, 21 due to diseases of the digestive system). 
 
3 Results 
After excluding participants for whom 25(OH)D measurements were not performed (n = 23), with 
missing data for key confounding variables (n = 44), or with extreme values for total daily energy 
intake (n = 100), a total of 2307 participants who died and 2923 subcohort participants (of whom 
266 died) remained for analysis (Supplementary Figure 1). 
 
Of the 2307 participants who died during a mean follow-up of 13.7 (SD 2.2) years, 1082 died due to 
cancer, 618 due to cardiovascular disease, and 119 due to respiratory diseases. Participants who 
8 
 
died were on average aged 61.3 (SD 7.2) years at baseline and 70.2 (SD 8.1) years at death. The 
number of deaths due to specific causes are shown in Supplementary Table 1. Characteristics of 
participants at the time of blood collection are shown in Table 1. Participants who died were more 
likely to be older, current or former smokers, have greater socioeconomic disadvantage, lower 
educational attainment, higher waist circumference, and to have a history of hypertension, history 
of cardiovascular disease, or diabetes at baseline. The median batch- and season-adjusted plasma-
equivalent 25(OH)D concentrations for subcohort participants and those who died were 49.1 
(interquartile range [IQR] 38.1–61.9) nmol/L and 47.6 (IQR 36.7–60.1) nmol/L, respectively. Within 
the subcohort, median 25(OH)D concentrations for women and men were 42.9 (IQR 34.8–53.0) and 
54.9 (IQR 43.0–68.8), respectively. 
 





n 2923 2307 
25(OH)D (nmol/L), sex-specific quartilesb   
1 730 (25.0) 659 (28.6) 
2 731 (25.0) 574 (24.9) 
3 732 (25.0) 562 (24.4) 
4 730 (25.0) 512 (22.2) 
Sex   
Women 1309 (44.8) 965 (41.8) 
Men 1614 (55.2) 1342 (58.2) 
Age (years)   
˂45 592 (20.3) 88 (3.8) 
45–54 988 (33.8) 341 (14.8) 
55–64 907 (31.0) 932 (40.4) 
≥65 436 (14.9) 946 (41.0) 
Country of birth   
Australia/New Zealand/Northern Europe 2443 (83.6) 1924 (83.4) 
Southern Europe 480 (16.4) 383 (16.6) 
Socioeconomic disadvantage   
1st quintile (most disadvantage) 383 (13.1) 407 (17.6) 
2nd quintile 478 (16.4) 482 (20.9) 
3rd quintile 483 (16.5) 379 (16.4) 
4th quintile 676 (23.1) 465 (20.2) 
5th quintile (least disadvantage) 903 (30.9) 574 (24.9) 
Educational attainment   
Primary school or less 331 (11.3) 413 (17.9) 
Some secondary school 1100 (37.6) 948 (41.1) 
Secondary school 693 (23.7) 532 (23.1) 







Waist circumference (cm), sex-specific quartilesc   
1 718 (24.6) 437 (18.9) 
2 733 (25.1) 458 (19.9) 
3 742 (25.4) 582 (25.2) 
4 730 (25.0) 830 (36.0) 
Physical activity   
None 596 (20.4) 476 (20.6) 
Low 571 (19.5) 419 (18.2) 
Moderate 998 (34.1) 958 (41.5) 
High  758 (25.9) 454 (19.7) 
Smoking status   
Never 1583 (54.2) 977 (42.3) 
Former  1017 (34.8) 918 (39.8) 
Current  323 (11.1) 412 (17.9) 
Alcohol intake (g/day)d   
Never drinker 656 (22.4) 625 (27.1) 
Former drinker 128 (4.4) 125 (5.4) 
Current low 687 (23.5) 504 (21.8) 
Current medium 699 (23.9) 418 (18.1) 
Current high 753 (25.8) 635 (27.5) 
Mediterranean diet score   
0–3 (low) 715 (24.5) 625 (27.1) 
4–6 (moderate) 1830 (62.6) 1435 (62.2) 
7–9 (high) 378 (12.9) 247 (10.7) 
Energy intake (kJ/day), sex-specific quartilese   
1 730 (25.0) 665 (28.8) 
2 731 (25.0) 570 (24.7) 
3 732 (25.0) 508 (22.0) 
4 730 (25.0) 564 (24.5) 
History of diabetes mellitus 78 (2.7) 188 (8.2) 
History of hypertension 532 (18.2) 754 (32.7) 
History of cardiovascular diseasef 184 (6.3) 385 (16.7) 
History of asthma 354 (12.1) 299 (13.0) 
All values are n (%). Sex-specific quartiles were formed from the distribution in the subcohort. 
a266 subcohort participants died. 
bQuartiles of batch- and season-adjusted plasma-equivalent 25(OH)D concentration in nmol/L: 
1, Women 13.9–34.7, Men 8.2–43.0 
2, Women 34.8–42.9, Men 43.1–54.8 
3, Women 43.0–53.0, Men 54.9–68.8 
4, Women 53.1–121.3, Men 68.9–201.8 
cQuartiles of waist circumference in cm: 
1, Women 52.0–70.6, Men 62.0–85.9  
2, Women 70.7–76.9, Men 86.0–91.9 
3, Women 77.0–85.9, Men 92.0–98.4 
4, Women 86.0–153.6, Men 98.5–143.0 
dCategories of alcohol intake for current drinkers in grams/day: 
Low: Women 0.1–4.2, Men 0.1–9.2 
Medium: Women 4.3–14.9, Men 9.3–25.7 
High: Women 15.0–157.9, Men 25.8–232.2 
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eQuartiles of energy intake in kJ/day: 
1, Women 3149–6302, Men 3755–7399 
2, Women 6303–8007, Men 7400–9192 
3, Women 8008–9827, Men 9193–11,397 
4, Women 9828–18,831, Men 11,398–22,150 
fHistory of angina, myocardial infarction, or stroke. 
 
 
Circulating 25(OH)D concentration was inversely associated with cancer mortality, with a 12% lower 
risk for each 25 nmol/L increment in 25(OH)D (HR = 0.88, 95% CI 0.78–0.99) and 24% lower risk 
comparing the highest with the lowest quartile (HR = 0.76, 95% CI 0.60–0.95) (Table 2). An inverse 
association was found for death due to colorectal cancer (HR per 25 nmol/L increment = 0.75, 95% CI 
0.57–0.99), with little evidence that this association differed by sex (P for interaction = 0.39), 
although it appeared to be slightly stronger for women (HR = 0.63, 95% CI 0.40–1.01) than for men 
(HR = 0.82, 95% CI 0.58–1.14). The HR for lung cancer mortality was similar in magnitude to that for 
overall cancer mortality but the estimate was accompanied by substantial uncertainty (HR = 0.90, 
95% CI 0.67–1.19). 25(OH)D was not associated with risk of death due to pancreatic cancer (HR = 
0.96, 95% CI 0.69–1.33), breast cancer (HR = 1.27, 95% CI 0.76–2.13), or prostate cancer (HR = 0.95, 
95% CI 0.67–1.35) (Figure 1). 
 
For death due to diseases of the respiratory system, there was a strong inverse association, with 
each 25 nmol/L increment in 25(OH)D associated with a 38% lower risk (HR = 0.62, 95% CI 0.43–
0.88). Considering subgroupings of respiratory diseases, strong inverse associations were evident for 
death due to chronic lower respiratory diseases, and specifically chronic obstructive pulmonary 
disease (COPD), with 43% (HR = 0.57, 95% CI 0.34–0.97) and 47% (HR = 0.53, 95% CI 0.30–0.94) 
lower risks per 25 nmol/L increment in 25(OH)D, respectively. 25(OH)D concentration was also 
strongly associated with risk of death due to diseases of the digestive system; each 25 nmol/L 
increment in 25(OH)D was associated with a 56% lower risk (HR = 0.44, 95% CI 0.26–0.76). 
 
The magnitude of the association for death due to endocrine, nutritional and metabolic diseases, 
and specifically diabetes mellitus, was suggestive of a moderate inverse association but estimates 
were imprecise due to the limited number of deaths due to these diseases (93 and 60, respectively) 
(Figure 1 and Table 2). 
 
The HRs for cardiovascular disease mortality were similar to those for all-cause mortality [11] and 
cancer mortality, but the CIs were wide (Figure 1 and Table 2). For death due to myocardial 
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infarction and cerebrovascular disease, estimates by 25(OH)D quartiles did not show any dose-
response relationship. There was little evidence that diseases of the nervous system were related to 
25(OH)D concentration (Table 2). 
 
 
Figure 1: Cause-specific mortality in relation to a 25 nmol/L increment in batch- and season-
adjusted plasma-equivalent 25-hydroxyvitamin D concentration. Hazard ratios (HRs) are plotted as 
squares, with the area of each square inversely proportional to the variance of the log HR, and 
corresponding 95% confidence intervals (CIs) are plotted as lines. Models were adjusted for the 







Table 2: Hazard ratios (HRs) and 95% confidence intervals (CIs) for cause-specific mortality in relation to circulating batch- and season-adjusted plasma-
equivalent 25(OH)D concentrations. Models for each cause of death were adjusted for the covariates listed in Supplementary Table 2. 
 Quartile 1 Quartile 2 Quartile 3 Quartile 4 P trend Per 25 nmol/L 
increment 
P 
 25(OH)D concentration (nmol/L), rangea    
Women                 13.9–34.7 34.8–42.9 43.0–53.0 53.1–121.3    
Men                       8.2–42.9 43.0–54.8 54.9–68.8 68.9–201.8    
Cause of death        
All causesb        
N 1318 1223 1239 1184  4964  
Deaths 659 574 562 512  2307  
HR (95% CI) 1.00 (ref) 0.87 (0.72–1.06) 0.85 (0.70–1.04) 0.74 (0.60–0.91) 0.005 0.86 (0.78–0.96) 0.007 
Cancer        
N 996 962 984 942  3884  
Deaths 293 267 281 241  1082  
HR (95% CI) 1.00 (ref) 0.90 (0.72–1.12) 0.90 (0.72–1.13) 0.76 (0.60–0.95) 0.03 0.88 (0.78–0.99) 0.03 
Colorectal cancer        
N 775 769 768 753  3065  
Deaths 46 48 39 30  163  
HR (95% CI) 1.00 (ref) 1.05 (0.68–1.63) 0.79 (0.50–1.26) 0.60 (0.36–0.98) 0.02 0.75 (0.57–0.99) 0.04 
Pancreatic cancer        
N 750 745 748 748  2991  
Deaths 20 14 18 19  71  
HR (95% CI) 1.00 (ref) 0.70 (0.33–1.47) 1.05 (0.51–2.17) 1.06 (0.50–2.22) 0.69 0.96 (0.69–1.33) 0.80 
Lung cancer        
N 781 777 763 768  3089  
Deaths 57 52 34 42  185  
HR (95% CI) 1.00 (ref) 1.05 (0.64–1.71) 0.66 (0.39–1.12) 0.85 (0.51–1.43) 0.28 0.90 (0.67–1.19) 0.45 
Breast cancerc        
N 337 334 347 341  1359  
Deaths 12 10 20 16  58  
HR (95% CI) 1.00 (ref) 0.73 (0.29–1.81) 1.45 (0.64–3.30) 1.08 (0.47–2.46) 0.45 1.27 (0.76–2.13) 0.36 
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 Quartile 1 Quartile 2 Quartile 3 Quartile 4 P trend Per 25 nmol/L 
increment 
P 
Prostate cancer        
N 413 425 423 414  1675  
Deaths 13 24 21 13  71  
HR (95% CI) 1.00 (ref) 1.82 (0.83–4.00) 1.38 (0.61–3.11) 0.75 (0.31–1.78) 0.29 0.95 (0.67–1.35) 0.79 
Other cancersd        
N 860 836 863 838  3397  
Deaths 145 119 149 121  534  
HR (95% CI) 1.00 (ref) 0.79 (0.59–1.04) 0.93 (0.70–1.22) 0.73 (0.55–0.98) 0.10 0.88 (0.75–1.03) 0.10 
Endocrine, nutritional and metabolic 
diseases 
       
N 760 755 751 742  3008  
Deaths 33 27 20 13  93  
HR (95% CI) 1.00 (ref) 0.96 (0.47–1.93) 0.88 (0.44–1.78) 0.51 (0.21–1.24) 0.16 0.79 (0.50–1.24) 0.31 
Diabetes mellitus        
N 756 747 741 736  2980  
Deaths 28 17 9 6  60  
HR (95% CI) 1.00 (ref) 0.92 (0.39–2.16) 0.64 (0.24–1.73) 0.36 (0.09–1.46) 0.13 0.64 (0.33–1.26) 0.20 
Diseases of the nervous system        
N 749 754 754 754  3011  
Deaths 19 30 23 24  96  
HR (95% CI) 1.00 (ref) 1.56 (0.84–2.90) 1.07 (0.55–2.07) 1.07 (0.55–2.08) 0.79 0.91 (0.66–1.24) 0.55 
Diseases of the circulatory system        
N 884 864 866 856  3470  
Deaths 176 155 146 141  618  
HR (95% CI) 1.00 (ref) 0.86 (0.63–1.18) 0.88 (0.64–1.20) 0.80 (0.58–1.11) 0.21 0.90 (0.76–1.07) 0.24 
Ischaemic heart disease        
N 816 803 797 804  3220  
Deaths 99 88 72 81  340  
HR (95% CI) 1.00 (ref) 0.89 (0.61–1.31) 0.79 (0.53–1.17) 0.84 (0.56–1.26) 0.32 0.91 (0.74–1.12) 0.37 
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 Quartile 1 Quartile 2 Quartile 3 Quartile 4 P trend Per 25 nmol/L 
increment 
P 
Myocardial infarction        
N 770 777 771 774  3092  
Deaths 48 53 41 48  190  
HR (95% CI) 1.00 (ref) 1.11 (0.69–1.78) 0.92 (0.55–1.53) 1.03 (0.62–1.73) 0.93 0.91 (0.70–1.17) 0.44 
Cerebrovascular disease        
N 758 762 765 760  3045  
Deaths 32 33 37 33  135  
HR (95% CI) 1.00 (ref) 0.99 (0.56–1.76) 1.15 (0.65–2.03) 0.91 (0.51–1.62) 0.87 0.92 (0.72–1.18) 0.51 
Diseases of the respiratory system        
N 772 755 755 742  3024  
Deaths 47 28 29 15  119  
HR (95% CI) 1.00 (ref) 0.67 (0.37–1.20) 0.63 (0.36–1.11) 0.34 (0.17–0.66) 0.002 0.62 (0.43–0.88) 0.007 
Chronic lower respiratory diseases        
N 754 743 742 735  2974  
Deaths 28 15 16 7  66  
HR (95% CI) 1.00 (ref) 0.57 (0.22–1.50) 0.61 (0.26–1.43) 0.30 (0.11–0.82) 0.03 0.57 (0.34–0.97) 0.04 
Chronic obstructive pulmonary disease        
N 750 741 741 733  2965  
Deaths 23 13 15 4  55  
HR (95% CI) 1.00 (ref) 0.61 (0.22–1.70) 0.70 (0.27–1.81) 0.22 (0.06–0.76) 0.04 0.53 (0.30–0.94) 0.03 
Diseases of the digestive system        
N 748 744 744 737  2973  
Deaths 21 15 13 7  56  
HR (95% CI) 1.00 (ref) 0.66 (0.31–1.40) 0.53 (0.23–1.25) 0.27 (0.11–0.71) 0.008 0.44 (0.26–0.76) 0.003 
aConcentration range of batch- and season-adjusted plasma-equivalent 25(OH)D in each quartile. 
bAll-cause mortality results have been published previously [11], and are reported here to facilitate comparisons with specific causes of death. 
cFemale breast cancer. 





3.1 Effect modification by baseline disease status 
There was suggestion of an inverse association between 25(OH)D and cardiovascular disease 
mortality for participants with a history of cardiovascular disease (n = 181 deaths; HR per 25 nmol/L 
increment = 0.82, 95% CI 0.58–1.15), but no association for those without cardiovascular disease at 
baseline (n = 437 deaths; HR = 1.00, 95% CI 0.84–1.18); however, the test of interaction had a large 
p-value (P for interaction = 0.30).  
 
3.2 Analyses excluding the first two years of follow-up 
Results were similar after excluding the first two years of follow-up, but there was no association for 
death due to myocardial infarction, while the associations for death due endocrine, nutritional and 
metabolic diseases and diabetes mellitus were slightly stronger (Supplementary Figure 2 and 
Supplementary Table 3). 
 
3.3 Participants in good, very good, or excellent health 
The association for cancer mortality was similar to that for all participants when restricted to those 
who rated their general health as good, very good, or excellent approximately four years after 
baseline blood collection (2681 participants, of whom 600 died due to cancer); HRs per 25 nmol/L 
increment in 25(OH)D and comparing the highest and lowest 25(OH)D quartiles were 0.86 (95% CI 
0.73–1.00) and 0.72 (95% CI 0.54–0.94), respectively. There was also suggestion of an inverse 
association between 25(OH)D and cardiovascular disease mortality for those who reported being in 
good, very good, or excellent health (2384 participants, of whom 270 died due to cardiovascular 
disease), but the CI included associations in either direction; HRs per 25 nmol/L increment in 
25(OH)D and comparing the highest and lowest 25(OH)D quartiles were 0.82 (95% CI 0.63–1.05) and 
0.69 (95% CI 0.44–1.08) respectively. 
 
4 Discussion 
In this cohort of middle-aged Australians without pre-baseline cancer, plasma-equivalent 25(OH)D 
concentration was inversely associated with death due to cancer (all malignant neoplasms 
combined), colorectal cancer, diseases of the respiratory system (particularly chronic lower 
respiratory diseases or COPD), and diseases of the digestive system. There was suggestion of an 
inverse association for death due to endocrine, nutritional and metabolic diseases (and specifically 
diabetes mellitus), but there were few deaths attributed to these diseases and estimates were 
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accompanied by substantial uncertainty. Similarly, estimates for an association with cardiovascular 
disease mortality lacked precision. We found little evidence for an association between circulating 
25(OH)D and death due to diseases of the nervous system. Results were similar in analyses excluding 
the first two years of follow-up. For participants who reported being in good, very good, or excellent 
health several years after baseline blood sample collection, the association for cancer mortality was 
similar to that for all participants, while for cardiovascular disease mortality there was suggestion of 
an inverse association that was slightly stronger than that for all participants, but estimates were 
imprecise.  
 
There are abundant data on the association between circulating 25(OH)D and all-cause mortality, 
but associations with specific causes of death remain uncertain [1]. Although numerous 
observational studies have investigated cancer and cardiovascular disease mortality, most existing 
studies have had insufficient cases to be able to examine specific causes of death beyond aggregate 
disease groupings. This may be problematic because these groupings can represent a heterogeneous 
set of diseases, which might be differently associated with vitamin D. A strength of this study was 
the relatively large number of deaths, which enabled investigation of several causes of death for 
which existing evidence is sparse. By evaluating specific cancer types, we found that higher 
circulating 25(OH)D might reduce mortality from colorectal cancer, but might not have any benefit 
for reducing mortality from pancreatic, breast, or prostate cancers. A limitation of our study was 
that there were insufficient deaths to investigate other cancers and we could not examine death due 
to specific types of diseases within some groups, such as diseases of the digestive system or nervous 
system. Substantial advantages of this study were the availability of extensive information on 
potential confounding variables, recruitment from one city (minimising any potential confounding 
effect of geographical location, including latitude), accurate and complete mortality data, and use of 
a highly sensitive and reliable LC-MS/MS assay for measurement of 25(OH)D. Nevertheless, the 
adjustments made for batch and seasonal effects, and the conversion from dried blood spot 
25(OH)D concentrations to plasma-equivalent 25(OH)D concentrations mean caution is necessary 
when interpreting the absolute 25(OH)D values. A further limitation was that concentration of 
25(OH)D was determined at only one time point; however, studies have shown consistency in 
25(OH)D measurements from individuals several years apart [16-18], suggesting a single 





The inverse association between 25(OH)D concentration and cancer mortality found in our study is 
consistent with the findings from two meta-analyses of cohort studies [2, 19], but there was no 
association reported by an individual participant data meta-analysis of standardised 25(OH)D [3]. In 
an individual participant data meta-analysis of cohort studies from Europe and the United States, 
there was no association between circulating 25(OH)D and cancer mortality for participants without 
a history of cancer, whereas there was an inverse association for participants with a history of 
cancer [5]. While this could reflect that vitamin D is perhaps more important for cancer progression 
and survival, it also raises the possibility that the association between 25(OH)D and cancer mortality 
might be due to reverse causation, whereby low 25(OH)D concentrations are the result of prevalent 
cancer and suboptimal health. Since our study was restricted to participants without a pre-baseline 
diagnosis of cancer, and 25(OH)D concentrations were ascertained before the diagnosis of cancer, 
we excluded this possibility. Further, the association was unchanged in sensitivity analyses excluding 
the first two years of follow-up or when restricted to participants in good to excellent health several 
years after baseline. Thus, reverse causation due to poor health is unlikely. Two Mendelian 
randomisation studies have yielded conflicting results; one found an inverse association between 
genetically-predicted 25(OH)D and cancer mortality [6], while an analysis of UK Biobank data did not 
find any association [20]. Meta-analyses of RCTs have shown that vitamin D supplementation was 
associated with reduced cancer mortality [7, 21, 22]. Subsequent to these meta-analyses, the results 
from two large-scale RCTs have also become available. In the Vitamin D Assessment (ViDA) trial 
involving 5108 New Zealanders, monthly supplementation with 100,000 IU vitamin D3 did not reduce 
cancer mortality, but only 60 deaths due to cancer accrued during follow-up in those without cancer 
before randomisation [23]. In the Vitamin D and Omega-3 Trial (VITAL) of 25,871 participants in the 
United States, daily 2000 IU vitamin D3 supplementation was associated with lower cancer mortality 
[24].  
 
Few studies have investigated the association between 25(OH)D concentration and cancer-specific 
mortality [1]. For colorectal cancer mortality, no association was found in a combined analysis of the 
Copenhagen City Heart Study (CCHS) and Copenhagen General Population Study (CGPS) [6], while 
separate analyses of NHANES III data have yielded results consistent with an inverse association, but 
with few cases [25-28]. To our knowledge, no other studies have investigated circulating 25(OH)D in 
relation to pancreatic cancer mortality. For lung cancer mortality, an inverse association was found 
in the CCHS and CGPS (combined) (HR per 20 nmol/L decrease in 25(OH)D = 1.28, 95% CI 1.06–1.54, 
which is equivalent to HR = 0.78, 95% CI 0.65–0.94 for a 20 nmol/L increment) [6], while in the 
Calcium Intake Fracture Outcome Study (CAIFOS), the estimate was imprecise with only 13 deaths 
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due to lung cancer (HR per 30 nmol/L decrease = 1.30, 95% CI 0.70–2.43; equivalent to 0.77, 95% CI 
0.41–1.43 per 30 nmol/L increment) [29]. There was little evidence of an association with lung 
cancer mortality in NHANES III (RR for 25(OH)D 80 to ˂100 nmol/L compared with ˂50 nmol/L = 0.99, 
95% CI 0.58–1.70) [27]. Two previous studies (CAIFOS and NHANES III) have investigated 25(OH)D in 
relation to breast cancer mortality, with no association found in CAIFOS based on 6 cases (HR per 30 
nmol/L decrease in 25(OH)D = 1.06, 95% CI 0.43–2.63; equivalent to 0.94, 95% CI 0.38–2.33 per 30 
nmol/L increment) [29], while in NHANES III there was suggestion of lower breast cancer mortality 
for higher 25(OH)D, but with only 53 cases the estimate had a wide CI (RR for 25(OH)D >80 versus 
˂50 nmol/L = 0.65, 95% CI 0.18–2.38) [27]. Consistent with our findings for prostate cancer 
mortality, evidence for an association was lacking in NHANES III [27, 28]. There is a paucity of data 
on pre-diagnostic 25(OH)D concentration and death due to cancers of other sites, necessitating 
further large studies with long follow-up durations and adequate power to evaluate these 
associations. In patients with certain cancers (including colorectal, pancreatic, breast, and prostate 
cancers), higher circulating 25(OH)D concentration has been associated with better survival [30-34]. 
It is therefore possible that vitamin D is more important for disease progression and prognosis than 
for prevention of cancer, warranting further investigations to disentangle the association of vitamin 
D with cancer incidence, mortality and survival.  
 
While many studies have investigated an association between circulating 25(OH)D and the risk of 
incident diabetes [35, 36], data on the relationship of 25(OH)D with diabetes mortality are lacking. 
We found a moderate inverse association between 25(OH)D concentration and death due to 
diabetes mellitus, as well as the collective group of endocrine, nutritional and metabolic diseases 
(which was reaffirmed in analyses excluding the first two years of follow-up), but there were 
relatively few deaths attributed to these causes and estimates were imprecise. It is possible that 
deaths due to diabetes mellitus are underestimated in death statistics because diabetes is often not 
recorded as the underlying cause of death, and this limits the ability to assess whether factors such 
as vitamin D status are associated with diabetes mortality. 
 
We did not find compelling evidence of an association between 25(OH)D concentration and 
cardiovascular mortality or death due to ischaemic heart disease. Considering results of both 
continuous and categorical analyses of 25(OH)D, there was little evidence that 25(OH)D 
concentration was associated with risk of death due to myocardial infarction or stroke. In another 
Australian cohort study, comprising participants of similar age but with higher 25(OH)D 
concentrations (mean 61 nmol/L) than the MCCS, and excluding those who died within the first two 
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years of follow-up, 25(OH)D was inversely associated with cardiovascular disease mortality [37]. 
Likewise, inverse associations between circulating 25(OH)D concentration and cardiovascular 
mortality have been reported in most observational studies [1]. However, the findings of these 
studies are not supported by data from a Mendelian randomisation study [6] or RCTs [7, 38], raising 
the possibility that results from observational studies might be biased by confounding and reverse 
causation [1]. Since people may change their diet and lifestyle when diagnosed with cardiovascular 
disease or after suffering a cardiovascular event such as a heart attack or stroke, we evaluated 
whether the association for cardiovascular disease mortality was modified by baseline disease 
status. While the test of interaction did not indicate a substantial difference, there was suggestion of 
an inverse association for participants with a history of cardiovascular disease but little evidence of 
an association for those without prior cardiovascular disease, suggesting that vitamin D might only 
have an effect on cardiovascular mortality in people with pre-existing disease. Nevertheless, 
25(OH)D concentration was inversely associated with cardiovascular disease mortality (albeit with 
imprecise estimates) for participants who rated their general health as good, very good, or excellent 
approximately four years after baseline blood sample collection. It is therefore not possible to rule 
out a potential association between 25(OH)D and cardiovascular mortality, particularly of small 
magnitude, or a role for vitamin D in cardiovascular disease survival post-diagnosis, and further 
research is required to examine these possibilities and elucidate whether vitamin D has any benefit 
for reducing mortality due to specific types of cardiovascular disease. 
 
Vitamin D status has been linked to several diseases of the nervous system, including multiple 
sclerosis [39] and Alzheimer’s disease [40], but associations with death due to these diseases remain 
unexplored. We did not find a lower risk of nervous system disease mortality for higher 25(OH)D 
concentrations. One other study has investigated the association between circulating 25(OH)D and 
death due to diseases of the nervous system, but with only 20 cases the estimate was imprecise (HR 
for highest versus lowest 25(OH)D quartile = 0.75, 95% CI 0.21–2.70) [41]. 
 
Six prospective cohort studies have assessed the association between 25(OH)D concentration and 
respiratory disease mortality, with all [6, 41-44] but one [45] showing a lower risk for higher 
25(OH)D, but these associations were based on relatively sparse data. In the MCCS, the inverse 
association for death due to diseases of the respiratory system appeared to be attributable to the 
relatively strong association for death due to COPD. A meta-analysis found that low 25(OH)D 
concentrations were associated with COPD severity and exacerbations [46], while a meta-analysis of 
RCTs found that vitamin D supplementation reduced the rate of moderate/severe COPD 
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exacerbations in those with low baseline 25(OH)D concentrations [47]. It is plausible that vitamin D 
sufficiency might be associated with improved COPD-related survival and further studies are 
required to confirm whether vitamin D can reduce mortality due to COPD and other respiratory 
diseases. 
 
The strong inverse association between 25(OH)D concentration and death due to diseases of the 
digestive system should be interpreted cautiously due to the limited number of cases, which 
prevented any appraisal of the relationship between 25(OH)D and specific diseases of the digestive 
system. Similar associations have been found by other studies, but these were also constrained by 
having few cases [16, 41]. While all studies thus far have found a strong inverse association, diseases 
of the digestive system are a diverse group of diseases with different aetiologies, and it remains 
unclear whether vitamin D is beneficial for reducing mortality due to all of these diseases. 
 
Observational studies are limited by the possibility of confounding and reverse causation and 
therefore cannot ascertain whether vitamin D is causally associated with mortality. Several large 
RCTs which were initiated over the last decade have so far found no effect of vitamin D3 
supplementation for cardiovascular disease mortality [23], while for cancer mortality, there was 
suggestion of a benefit in VITAL [24] but no effect in ViDA [23]. It is possible that the follow-up time 
in these trials is not yet adequate for sufficient cases to accrue. In addition, existing trials are unlikely 
to have sufficient power to examine specific causes of death other than cardiovascular disease and 
cancer, both of which comprise heterogeneous groups of diseases. Further, these trials included a 
majority of participants who already had adequate 25(OH)D concentrations at baseline, and it is 
suggested that vitamin D supplementation will confer little benefit to these individuals [48, 49]. 
While future results from other large RCTs (such as D-Health [50]) might help elucidate whether 
vitamin D can reduce mortality due to certain diseases, further large long-term cohort studies are 
required to provide information about the relationship between vitamin D and mortality, particularly 
for less common causes of death.  
 
5 Conclusions 
Overall, our results suggest that vitamin D might be important for preventing death due to some 
cancers, particularly colorectal cancer, as well as death due diseases of the respiratory system and 
diseases of the digestive system. Diabetes mortality appeared to be inversely related to 25(OH)D 
concentration in the MCCS. The relationship between circulating 25(OH)D and cardiovascular disease 
mortality remains uncertain. Further large long-term cohort studies and RCTs are required to 
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confirm these findings and explore associations with rarer causes of death so that appropriate 
clinical guidelines for vitamin D requirements in chronic diseases can be established. 
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